Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;23(7):1917-1924.
doi: 10.1007/s10461-018-2376-y.

Predictors of PrEP Uptake Among Patients with Equivalent Access

Sarit A Golub  1   2 , Rachel A Fikslin  3 , Matthew H Goldberg  3 , Stephanie M Peña  4 , Asa Radix  4
Affiliations

Predictors of PrEP Uptake Among Patients with Equivalent Access

Sarit A Golub et al. AIDS Behav. 2019 Jul.

Abstract

Increasing PrEP adoption for eligible individuals is critical, but limited research has examined individual-level factors that might be amenable to educational or behavioral intervention. Using data from a PrEP demonstration project conducted at a community health center, we examined differences in behavioral and psychosocial factors between patients offered PrEP who chose to accept it and those who declined. In a multivariable model, the odds of accepting PrEP were higher among those with an HIV-positive main partner, greater risk behavior in the past 3 months, and higher HIV risk perception. PrEP adoption was positively associated with PrEP adherence self-efficacy and negatively associated with perceived sensitivity to medicines. These psychological variables were associated with measures of PrEP- and HIV-related stigma. In the multivariable model, there were no differences in PrEP adoption by demographic factors or socioeconomic status. Data suggest that patients' decisions about PrEP uptake may be impacted not only by objective and subjective HIV risk, but also by psychological variables such as stigma beliefs, medication beliefs, and self-efficacy.

Keywords: HIV prevention; Implementation; Pre-exposure prophylaxis (PrEP); Self-efficacy; Stigma.

PubMed Disclaimer

References

    1. Hess KL, Johnson AS, Hu X, Li J, Wu B, Yu C, et al. Diagnoses of HIV infection in the United States and dependent areas, 2016 2017.
    1. Food U, Administration D. Truvada for PrEP fact sheet: Ensuring safe and proper use 2014.
    1. Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep 2015;64(46):1291–5. - PubMed
    1. Parsons JT, Rendina HJ, Lassiter JM, Whitfield TH, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 2017;74(3):285–92. - PMC - PubMed
    1. Hood JE, Buskin SE, Dombrowski JC, Kern DA, Barash EA, Katzi DA, et al. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. Aids 2016;30(3):515–9. - PubMed